About Variantyx
Variantyx is a Healthcare company based in Boston (United States) founded in 2014 by Haim Neerman and Tomer Jackman. Genomics data analysis platform for healthcare diagnostics is offered. Variantyx has raised $110.5 million across 6 funding rounds from investors including IBM, Kreos Capital and Bosch Ventures. The company has 122 employees. Its chief executive, as recorded, is Haim Neerman. Variantyx offers products and services including Genomic Unity® 2.0, Exome Plus Analysis, Exome Analysis, and Comprehensive Hereditary Cancer Analysis. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is VARIANTYX, INC. Its competitors include Natera, ArcherDX and ImaginAb; 3 of its 3 listed competitors have raised funding.
Company details
Variantyx was founded in 2014 and is headquartered in Boston, United States. An integrated platform is provided for the analysis, interpretation, and reporting of next-generation sequencing data in the genomics sector. Whole-genome sequencing data is utilized through partnerships with sequencing providers, followed by automated processing and clinical report generation. Comprehensive molecular diagnostics are delivered for various disease areas in healthcare settings.
- Headquarters Boston, United States
- Employees 122
- Founders Haim Neerman, Tomer Jackman
- SectorsHealthcare
- Email••••••••
- Website variantyx.com
- Social LinkedIn X Facebook Instagram
- Legal Name Variantyx, Inc.
- Total Equity Funding$110.5M (USD)
in 6 rounds
- Latest Funding Round$36M (USD), Series C
Apr 2024
- InvestorsIBM
& 9 more
- Employee Count122
Products & Services of Variantyx
Variantyx offers a comprehensive portfolio of products and services, including Genomic Unity® 2.0, Exome Plus Analysis, Exome Analysis, and Comprehensive Hereditary Cancer Analysis.
Comprehensive analysis for genetic disorders using whole genome sequencing
Targeted genetic testing for specific disorders
In-depth examination of exome for diagnostic purposes
Genetic evaluation for hereditary cancer risks
Funding Insights of Variantyx
Variantyx has successfully raised a total of $110.5M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $36 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $110.5M
- Total Rounds 6
- Last Round Series C — $36M
- First Round $7M
(Jun 2019)
- Investors Count 10
All 6 funding rounds of Variantyx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | $36M | Series C | – | – | |
| Oct 2023 | Series C | – | – | ||
| Oct 2022 | $21M | Debt – Conventional | – | – | |
| Feb 2022 | $41.5M | Series C | – | New Era Capital Partners | |
| Mar 2021 | $26M | Series C | – | GF Financial Markets, Quark Venture | |
| Jun 2019 | $7M | Series A | – | Pitango | – |
10 investors in total: 10 institutional.
Investors in Variantyx
Variantyx has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include IBM, Kreos Capital and Bosch Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are made in innovative technology startups. | rbvc.com | Stuttgart, Germany | ||
Venture capital investments in tech and healthtech sectors through dedicated funds. | pitango.com | |||
Early-stage tech startups are funded by the venture capital firm. | neweracp.com | Tel Aviv, Israel | ||
Early-stage investments are made in healthcare technology and life sciences. | 2020hcp.com | Auburndale, United States | ||
Peregrine is focused on healthcare innovation through strategic global investments. | peregrinevc.com | Or Yehuda, Israel | ||
Tech & Life Sciences focused early stage VC firm investing in North America | quarkventure.com | Vancouver, Canada | ||
Venture capital firm investing in tech startups | bosch.ventures | Gerlingen, Germany | ||
Venture debt is provided to growth-stage companies across multiple sectors. | 1998 | kreoscapital.com | London, United Kingdom | |
| gffm.com | ||||
Hybrid cloud and DevOps automation are delivered to enterprises. | 1911 | ibm.com | United States |
Investor details for Variantyx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Variantyx
73 people are tracked at Variantyx (19 in leadership, 5 in board & advisors, 49 in team); the tracked headcount is 122.
| Name | Role | Group |
|---|---|---|
Haim Neerman | Co-Founder & CEO | Leadership |
Tomer Jackman | Co-Founder | Leadership |
Raewyn McCombs | Director Of Clinical Laboratory Quality | Leadership |
Shane Hussey | Head Of NGS Data Science | Leadership |
Yaron Rachmany | COO | Leadership |
Christopher Zerwas | VP Sales | Leadership |
Michael Martin | Director of Technology Operations | Leadership |
Alexander Kaplun | VP Product | Leadership |
Shira Modai | VP Project Management | Leadership |
Nadav Hirsch | Director Of Business Applications | Leadership |
Allan J. Fisher, MD, FACOG, FACMG | Medical Director | Leadership |
Donna Cash | National Sales Director Reproductive Genomics | Leadership |
Thomas DeLuca (MBTI) | Chief Human Resources Officer | Leadership |
Eyal Reinstein | Chief Medical Officer | Leadership |
Nurit Dror | VP of Information Systems | Leadership |
Shirel Weiss | VP Of Marketing | Leadership |
Moises Serrano | Laboratory Director | Leadership |
Geovana Laginestra | Associate Director Of Laboratory Operations | Leadership |
Christine Stanley | Chief Director Clinical Genomics | Leadership |
Zafrira Avnur | Board Member | Board & advisors |
53 more people are available in the full profile.
Complete people profiles for Variantyx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Variantyx
3 dated milestones of Variantyx across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Variantyx is founded.
- Funding First funding round of $7.0M.
- Funding Latest funding round, Series C, of $36.0M.
Competitors of Variantyx
Variantyx has 3 listed competitors in our database, 3 of them funded. They include Natera, ArcherDX and ImaginAb.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| imaginab.com | 2007 | Los Angeles, United States | $59.64M | 17 | ImaginAb is focused on developing advanced immuno-oncology imaging technologies. |
Detailed competitors of Variantyx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Variantyx
The website of Variantyx (variantyx.com) receives about 9.5K visits a month.
- Monthly visits9.5K
▲ 7.5% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Variantyx (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Variantyx
Complete news archive for Variantyx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Variantyx
Variantyx was founded in 2014 and raised its 1st funding round 5 years after it was founded.
Variantyx is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Haim Neerman is the CEO of Variantyx, as recorded in our data. They have also founded this company.
Variantyx is a funded company, having raised a total of $110.5M across 6 funding rounds to date. The company's 1st funding round was a Series A of $7M, raised on Jun 2019.
Variantyx has 122 employees.
Variantyx was founded in 2014 and is headquartered in Boston, United States. An integrated platform is provided for the analysis, interpretation, and reporting of next-generation sequencing data in the genomics sector. Whole-genome sequencing data is utilized through partnerships with sequencing providers, followed by automated processing and clinical report generation. Comprehensive molecular diagnostics are delivered for various disease areas in healthcare settings.
Variantyx offers Genomic Unity® 2.0, Exome Plus Analysis, Exome Analysis, and Comprehensive Hereditary Cancer Analysis.
Variantyx has 10 investors. Key investors include IBM, Kreos Capital, Bosch Ventures, Pitango, and New Era Capital Partners.
Variantyx operates through Variantyx, Inc..